Background
This case involves a patent (Patent No. 4332353) covering compositions containing 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 for treating drug-induced constipation caused by opioid compounds (such as morphine) or anticholinergic drugs. The patent, which issued in 2009 based on a 2002 application with a priority date of May 2001, covered a novel use of prostaglandin compounds to counteract the gastrointestinal side effects of pain medications and psychiatric drugs without diminishing their therapeutic effects.
The plaintiff filed an invalidation request with the Japanese Patent Office in December 2023, asserting four grounds for invalidity: lack of inventive step (obviousness), lack of enabling disclosure, lack of adequate support in the specification, and lack of clarity. The Patent Office rejected all four grounds on April 22, 2024, upholding the patent. The plaintiff appealed to the Intellectual Property High Court.
The defendant was the original patent assignee, Scampo (later renamed Scampo Gesellschaft mit beschränkter Haftung), which subsequently transferred the patent rights to the present defendant in December 2024. The trial proceeded with arguments on whether the claimed invention would have been obvious to a person skilled in the art based on prior publications and technical knowledge available at the priority date.
The Court’s Holding
The Intellectual Property High Court unanimously dismissed the plaintiff’s appeal and affirmed the Patent Office’s decision upholding the patent’s validity. The court found the claimed invention was not obvious in light of the prior art and possessed properties not predictable at the priority date.
The central issue concerned whether skilled artisans would have been motivated to modify a structurally similar prostaglandin compound (PGE2 with a methyl ester) disclosed in the closest prior art (Japanese Patent 2-109) into the claimed compound (PGE1 as a free acid) and apply it to treat drug-induced constipation rather than as a general laxative. The prior art compound had been identified as particularly effective because it possessed all three “preferred” structural features identified in the prior art. The court found no adequate motivation to depart from this already-optimized structure by changing the 5-6 carbon bond from a double bond to a single bond and converting the methyl ester to a free acid. The plaintiff’s arguments that the compounds were known, that the synthesis pathway was disclosed in a general synthetic scheme, or that such structural variations were routine medical chemistry all failed because they did not address the specific motivation to combine these teachings for the specific purpose of treating drug-induced constipation.
Regarding non-obvious effects, the court emphasized that the experimental evidence in the specification demonstrated: (1) the compound effectively counteracts opioid-induced constipation at low doses in a dose-dependent manner; (2) the compound does not interfere with morphine’s analgesic effects even at high doses; and (3) standard laxatives (sennosides and picosulfate sodium) used clinically for constipation management do not effectively treat opioid-induced constipation. The court found these results unexpected and unpredictable from the prior art, which suggested that drugs with “intestinal contraction action” mechanisms were preferred for drug-induced constipation treatment—a mechanism the prior art’s compound notably lacked. The specification’s animal testing methodology using charcoal markers to assess intestinal transit was recognized as an established practice in the art and did not undermine the evidential value of the results.
Key Takeaways
- Obviousness requires motivation. Even when individual elements of an invention are known and a skilled artisan possesses general knowledge, the combination is not obvious without adequate motivation to depart from the preferred embodiments of the prior art—particularly when the prior art compound had demonstrated superior results.
- New therapeutic use is not obvious from general laxative properties. The court recognized that treating drug-induced constipation is a distinct technical problem requiring different solutions than general constipation treatment, and prior art directed to general laxatives does not teach or suggest their use for this specific medical indication.
- Unpredictable effects in pharmaceutical patents warrant protection. When a pharmaceutical composition demonstrates results not predictable from known structural variations—such as maintaining a drug’s therapeutic efficacy while counteracting its side effects—the invention may be patentable even if the individual components are known.
- Sound experimental methodology supports patentability. Established testing protocols accepted by the scientific community (here, charcoal meal testing for intestinal transit) validate the specification’s enabling disclosure and support requirements, even if those protocols differ in some procedural details from other accepted variations.
Why It Matters
This decision reinforces important principles in pharmaceutical patent law concerning both inventive step and the scope of prior art disclosures. The court’s holding that a known compound applied to a new therapeutic indication, even with known structural variants available in the prior art, is not obvious so long as there is no specific teaching or motivation for the particular combination, protects innovators who identify new medical applications for existing chemical scaffolds. This is especially significant for drug repurposing and side-effect mitigation strategies—areas where pharmaceutical development frequently advances by identifying unexpected beneficial properties of known compounds or their analogues.
The decision also clarifies standards for support and enablement in specifications for pharmaceutical patents. By confirming that established animal testing methodologies—even when conducted with reasonable procedural variations suited to the specific research question—provide adequate enablement and support, the court avoided imposing unduly rigid requirements that could discourage pharmaceutical innovation. The ruling reflects a balanced approach: requiring sufficient evidence that the claimed effects are real and unexpected, while respecting the practical flexibility necessary in experimental design. For companies developing treatments for medication side effects and prosecutors seeking patent protection for such innovations, the decision provides welcome confirmation that this emerging therapeutic area merits robust patent protection.